RTTNews | Sep 7, 2021 11:09AM EDT

11:09 Tuesday, September 7, 2021 (RTTNews.com) - Shares of Lexaria Bioscience Corp. (LEXX) gained over 6% on Tuesday morning after the company reported positive initial data from human clinical study HYPER-H21-2 evaluating DehydraTECHTM-processed cannabidiol for potential application against hypertension.

LEXX is currently trading at $6.69, up $0.39 or 6.19%, on the Nasdaq, on a volume of 3.9 million shares, above three-month average volume of 1 million shares.

The company said Human Clinical Study HYPER-H21-2 evidences up to a remarkable 23% decrease in blood pressure with patented DehydraTECH-CBD relative to placebo.

Read the original article on RTTNews ( https://www.rttnews.com/3223772/lexaria-bioscience-shares-up-6-on-positive-initial-data-from-hypertension-treatment-trial.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved